Cidara Therapeutics, Inc. (CDTX) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$221.38
Price Target
$221.50
Target Range
$221.50 — $221.50
Analyst Rating
Buy
Forward P/E—
Trailing P/E-8.3x
Forward PEG—
Implied Growth+47.5%
Median Target$221.50
Analyst Spread0.0%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$222
+0.1%
Consensus
$222
+0.1%
Bull Case
$222
+0.1%
CDTX Price Target Analysis
Updated May 6, 2026As of May 6, 2026, Cidara Therapeutics, Inc. (CDTX) has a Wall Street consensus price target of $221.50, based on estimates from 11 covering analysts. With the stock currently trading at $221.38, this represents a potential upside of +0.1%. The company has a market capitalization of $6.96B.
Analyst price targets range from a low of $221.50 to a high of $221.50, representing a 0% spread in expectations. The median target of $221.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 8 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CDTX trades at a trailing P/E of -8.3x. Analysts expect EPS to grow +47.5% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+119.5%
Avg Forward P/E17.9x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ACADACADIA Pharmaceuticals Inc. | $3.7B | $21.48 | $34.78 | +61.9% | Buy | 48.5x | 37 |
 AGIOAgios Pharmaceuticals, Inc. | $1.6B | $26.98 | $37.75 | +39.9% | Buy | — | 29 |
 PRAXPraxis Precision Medicines, Inc. | $7.6B | $337.95 | $544.40 | +61.1% | Buy | — | 16 |
 ENTAEnanta Pharmaceuticals, Inc. | $442M | $15.24 | $48.20 | +216.3% | Buy | — | 19 |
 MGNXMacroGenics, Inc. | $191M | $3.01 | $6.00 | +99.3% | Buy | — | 22 |
 AMPHAmphastar Pharmaceuticals, Inc. | $1.1B | $23.90 | $26.00 | +8.8% | Hold | 7.4x | 12 |
 CMPXCompass Therapeutics, Inc. | $330M | $1.85 | $11.20 | +505.7% | Buy | — | 15 |
 ARDXArdelyx, Inc. | $1.7B | $7.10 | $17.00 | +139.4% | Buy | — | 16 |
 TBPHTheravance Biopharma, Inc. | $858M | $16.94 | $27.00 | +59.4% | Hold | 6.7x | 16 |
 PFEPfizer Inc. | $150.8B | $26.50 | $27.27 | +2.9% | Hold | 9.0x | 39 |
Upside Potential Comparison
CMPXENTAARDXMGNXACADPRAXTBPHAGIOSee CDTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CDTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CDTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCDTX — Frequently Asked Questions
Quick answers to the most common questions about buying CDTX stock.
What is the CDTX stock price target for 2026?
The consensus price target for CDTX is $221.5, close to the current price of $221.38 (0.1% implied move). Based on 11 analyst estimates, the stock appears fairly valued near current levels.
Is CDTX a buy, sell, or hold?
CDTX has a consensus rating of "Buy" based on 11 Wall Street analysts. The rating breakdown is predominantly bullish, with 8 Buy/Strong Buy ratings. The consensus 12-month price target of $221.5 implies 0.1% upside from current levels.
Is CDTX stock overvalued or undervalued?
CDTX's current price is $221.38 with a consensus target of $221.5 (0.1% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
How high can CDTX stock go?
The most bullish Wall Street analyst has a price target of $221.5 for CDTX, while the most conservative target is $221.5. The consensus of $221.5 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover CDTX stock?
CDTX is moderately covered, with 11 analysts providing price targets and ratings. Of these, 1 have Strong Buy ratings, 7 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the CDTX stock forecast?
The 12-month CDTX stock forecast based on 11 Wall Street analysts shows a consensus price target of $221.5, with estimates ranging from $221.5 (bear case) to $221.5 (bull case). The median consensus rating is "Buy".
Should I buy CDTX stock?
CDTX appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $221.5 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do CDTX price targets vary so much?
CDTX analyst price targets range from $221.5 to $221.5, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $221.5 consensus represents the middle ground.